Strand Biotech

Strand Therapeutics is a clinical-stage biotechnology company developing the next generation of mRNA-based therapies through a proprietary programmable mRNA platform. By integrating synthetic biology with mRNA therapeutics, the company creates "smart" mRNA molecules capable of sensing their cellular environment and controlling the location, timing, and intensity of protein expression. Their lead program, STX-001, is an mRNA-based therapy designed to express IL-12 directly within the tumor microenvironment to trigger a potent anti-tumor immune response while minimizing systemic toxicity. Strand's technology aims to overcome the limitations of traditional mRNA by enabling precise, multi-functional, and long-lasting therapeutic effects across oncology and other complex diseases.